Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia The management of chronic myeloid leukemia (CML) has been revolutionized by the discovery of tyrosine kinase inhibitors (TKIs) against BCR-ABL1 oncogenic fusion protein. Imatinib, the first BCR-ABL1 TKI, was introduced into clinical practice in the early 2000s. In the following years, the so-called second-generation TKIs (2GTKIs)—dasatinib, nilotinib, and bosutinib were approved, initially for patients resistant to imatinib, and subsequently for front-line treatment. With multiple TKIs available, selection of first-line therapy is challenging. CML risk, patient characteristics and potential toxicities of different TKIs play a fundamental role, in particular when deciding between imatinib and 2GTKIs as frontline treatment. So, when deciding front-line therapy for a patient with CML in the chronic phase (CML-CP), clinicians must consider both the long-term outcomes, such as overall survival and progression-free survival, as well as safety, tolerance and possible treatment discontinuation. This paper offers a practical algorithmic approach for the sequential use of commercially available TKIs in patients with CML-CP along with the data available in the literature. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia

Tiribelli, Mario; Eskazan, Ahmet
Oncology and Therapy , Volume 7 (2) – Aug 8, 2019
Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/tyrosine-kinase-inhibitor-sequencing-in-patients-with-chronic-myeloid-cDYA05330W
Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-00098-w
Publisher site
See Article on Publisher Site

Abstract

The management of chronic myeloid leukemia (CML) has been revolutionized by the discovery of tyrosine kinase inhibitors (TKIs) against BCR-ABL1 oncogenic fusion protein. Imatinib, the first BCR-ABL1 TKI, was introduced into clinical practice in the early 2000s. In the following years, the so-called second-generation TKIs (2GTKIs)—dasatinib, nilotinib, and bosutinib were approved, initially for patients resistant to imatinib, and subsequently for front-line treatment. With multiple TKIs available, selection of first-line therapy is challenging. CML risk, patient characteristics and potential toxicities of different TKIs play a fundamental role, in particular when deciding between imatinib and 2GTKIs as frontline treatment. So, when deciding front-line therapy for a patient with CML in the chronic phase (CML-CP), clinicians must consider both the long-term outcomes, such as overall survival and progression-free survival, as well as safety, tolerance and possible treatment discontinuation. This paper offers a practical algorithmic approach for the sequential use of commercially available TKIs in patients with CML-CP along with the data available in the literature.

Journal

Oncology and Therapy – Springer Journals

Published: Aug 8, 2019

References

  • Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial
    Cortes, JE; Saglio, G; Kantarjian, HM
  • Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
    Hochhaus, A; Saglio, G; Hughes, TP
  • Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events—is better always good?
    Eskazan, AE; Ozmen, D
  • Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): clinical characteristics of chronic myeloid leukemia (CML) patients treated in real-life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group
    Specchia, G; Pregno, P; Nicolosi, M
  • Long-term outcomes of imatinib treatment for chronic myeloid leukemia
    Hochhaus, A; Larson, RA; Guilhot, F
  • Assessment of Imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
    Hehlmann, R; Lauseker, M; Saussele, S
  • Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib
    Nicolini, FE; Alcazer, V; Cony-Makhoul, P
  • Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
    Shah, NP; Rousselot, P; Schiffer, C
  • Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    Giles, FJ; Coutre, PD; Pinilla-Ibarz, J
  • Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase
    Cony-Makhoul, P; Gardembas, M; Coiteux, V
  • Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
    Tiribelli, M; Bonifacio, M; Binotto, G
  • Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors
    Russo Rossi, A; Breccia, M; Abruzzese, E
  • Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature
    Ongoren, S; Eskazan, AE; Suzan, V
  • Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
    Cortes, JE; Kim, DW; Pinilla-Ibarz, J
  • Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
    Molica, M; Scalzulli, E; Colafigli, G
  • Evolving treatment strategies in CML—moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?
    Eşkazan, AE
  • Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE Trial
    Cortes, JE; Gambacorti-Passerini, C; Deininger, MW
  • Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial
    Cortes, JE; Saglio, G; Kantarjian, HM
  • Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
    Hochhaus, A; Saglio, G; Hughes, TP
  • Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
    Saussele, S; Richter, J; Guilhot, J
  • Treatment-free remission with first- and second-generation tyrosine kinase inhibitors
    Cortes, J; Rea, D; Lipton, JH
  • Allogeneic haematopoietic stem cell transplantation for chronic myeloid leukaemia in the era of tyrosine kinase inhibitors
    Eskazan, AE; Tiribelli, M